Market Overview

Vetr Upgrades Valeant


The Vetr crowd downgraded Valeant Pharmaceuticals International, Inc. (NASDAQ: VRX) from 4 stars to 4.5 stars.

The crowd rates Valeant a Buy with a price target of $19.72. Wall Street analysts price the stock's value at $24.58.

See how crowdsourced ratings can help predict the market?

Valeant shares were trading up slightly at $17.75 after Tuesday's close.

For the crowd's full analysis of the stock, click here.

Posted-In: VetrUpgrades Crowdsourcing Analyst Ratings General


Related Articles (VRX)

View Comments and Join the Discussion!

Latest Ratings

SYBXChardan CapitalInitiates Coverage On20.0
GEJP MorganUpgrades6.0
FEYEMorgan StanleyDowngrades21.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Henry Schein, Patterson Companies Downgraded On Amazon Fears

Tap Tech In Israel With This New ETF